Kolexia
Duluc Muriel Médecine générale
Duluc Muriel
Médecine générale
Hôpital La Timone
Marseille, France
42 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs neuroendocrines Tumeurs du foie Métastase tumorale Tumeurs osseuses Tumeurs hématologiques Tumeurs des glandes endocrines Tumeurs du péritoine COVID-19 Tumeurs gastro-intestinales

Collaborateurs

Voir plus
Dahan Laetitia
Dahan Laetitia
Hôpital La Timone, Marseille, France
Norguet-Monnereau Emmanuelle
Norguet-Monnereau Emmanuelle
Hôpital La Timone, Marseille, France
Seitz Jean-Francois
Seitz Jean-Francois
Hôpital La Timone, Marseille, France
Lepage Come
Lepage Come
Hôpital François Mitterrand, Dijon, France

Industries

Voir plus
Servier
5 collaboration(s)
Dernière en 2023
B3TSI
4 collaboration(s)
Dernière en 2022
A+A
2 collaboration(s)
Dernière en 2023
IQVIA
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.
Cancer discovery   03 juin 2022
Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer.
Journal of geriatric oncology   16 mai 2022
EVACEL: Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   27 mars 2020
Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.
European journal of cancer (Oxford, England : 1990)   31 octobre 2019
ChimioAge: Cohort of Patients> 70 Years Old With Cancer and / or Hematological Malignancy Treated With Chemotherapy and / or Immunotherapy and / or Targeted Therapy and / or New Generation Hormone Therapy After Oncogeriatric Evaluation and Therapeutic Revision on Public Assistance -Hospitals From Marseille
Essai Clinique (Assistance publique - Hôpitaux de Marseille)   21 mai 2019
Everolimus after transarterial liver therapy of metastases from gastrointestinal neuroendocrine tumors: The FFCD 1104-EVACEL-GTE phase II study
Abstract Book of the 43rd ESMO Congress (ESMO 2018) 19–23 October 2018, Munich, Germany   01 octobre 2018
Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Abstract Book of the 43rd ESMO Congress (ESMO 2018) 19–23 October 2018, Munich, Germany   01 octobre 2018
Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics
Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark   01 octobre 2016
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.
British journal of clinical pharmacology   28 novembre 2015
Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.
Pharmacogenomics   13 février 2014